These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 11241306)
1. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Kamarashev J; Ferrone S; Seifert B; Böni R; Nestle FO; Burg G; Dummer R Int J Cancer; 2001 Jan; 95(1):23-8. PubMed ID: 11241306 [TBL] [Abstract][Full Text] [Related]
2. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Kageshita T; Hirai S; Ono T; Hicklin DJ; Ferrone S Am J Pathol; 1999 Mar; 154(3):745-54. PubMed ID: 10079252 [TBL] [Abstract][Full Text] [Related]
3. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Bandoh N; Ogino T; Katayama A; Takahara M; Katada A; Hayashi T; Harabuchi Y Oncol Rep; 2010 Apr; 23(4):933-9. PubMed ID: 20204276 [TBL] [Abstract][Full Text] [Related]
4. Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. Kishore R; Hicklin DJ; Dellaratta DV; Golde U; Kageshita T; Seliger B; Ferrone S Tissue Antigens; 1998 Feb; 51(2):129-40. PubMed ID: 9510369 [TBL] [Abstract][Full Text] [Related]
5. Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Singal DP; Ye M; Ni J; Snider DP Immunol Lett; 1996 May; 50(3):149-54. PubMed ID: 8803612 [TBL] [Abstract][Full Text] [Related]
6. Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Thor Straten P; Kirkin AF; Seremet T; Zeuthen J Int J Cancer; 1997 Mar; 70(5):582-6. PubMed ID: 9052759 [TBL] [Abstract][Full Text] [Related]
7. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Seliger B; Atkins D; Bock M; Ritz U; Ferrone S; Huber C; Störkel S Clin Cancer Res; 2003 May; 9(5):1721-7. PubMed ID: 12738726 [TBL] [Abstract][Full Text] [Related]
8. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Cabrera CM; Jiménez P; Cabrera T; Esparza C; Ruiz-Cabello F; Garrido F Tissue Antigens; 2003 Mar; 61(3):211-9. PubMed ID: 12694570 [TBL] [Abstract][Full Text] [Related]
9. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Facoetti A; Nano R; Zelini P; Morbini P; Benericetti E; Ceroni M; Campoli M; Ferrone S Clin Cancer Res; 2005 Dec; 11(23):8304-11. PubMed ID: 16322289 [TBL] [Abstract][Full Text] [Related]
10. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633 [TBL] [Abstract][Full Text] [Related]
11. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Vitale M; Pelusi G; Taroni B; Gobbi G; Micheloni C; Rezzani R; Donato F; Wang X; Ferrone S Clin Cancer Res; 2005 Jan; 11(1):67-72. PubMed ID: 15671529 [TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases. Müller M; Agaimy A; Zenk J; Ettl T; Iro H; Hartmann A; Seliger B; Schwarz S Histopathology; 2013 May; 62(6):847-59. PubMed ID: 23611358 [TBL] [Abstract][Full Text] [Related]
13. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? Atkins D; Ferrone S; Schmahl GE; Störkel S; Seliger B J Urol; 2004 Feb; 171(2 Pt 1):885-9. PubMed ID: 14713847 [TBL] [Abstract][Full Text] [Related]
14. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors. Tao J; Li Y; Liu YQ; Li L; Liu J; Shen X; Shen GX; Tu YT Br J Dermatol; 2008 Jan; 158(1):88-94. PubMed ID: 17999701 [TBL] [Abstract][Full Text] [Related]
15. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Romero JM; Jiménez P; Cabrera T; Cózar JM; Pedrinaci S; Tallada M; Garrido F; Ruiz-Cabello F Int J Cancer; 2005 Feb; 113(4):605-10. PubMed ID: 15455355 [TBL] [Abstract][Full Text] [Related]
16. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma. Seliger B; Dunn T; Schwenzer A; Casper J; Huber C; Schmoll HJ Scand J Immunol; 1997 Dec; 46(6):625-32. PubMed ID: 9420627 [TBL] [Abstract][Full Text] [Related]
17. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Hicklin DJ; Kageshita T; Ferrone S Tissue Antigens; 1996 Jul; 48(1):38-46. PubMed ID: 8864173 [TBL] [Abstract][Full Text] [Related]
18. Distribution of HLA-A, B alleles and polymorphisms of TAP and LMP genes in Korean patients with atopic dermatitis. Lee HJ; Ha SJ; Han H; Kim JW Clin Exp Allergy; 2001 Dec; 31(12):1867-74. PubMed ID: 11737038 [TBL] [Abstract][Full Text] [Related]
19. [Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in laryngeal squamous cell carcinoma]. Zeng Q; Wang XL; Xu ZG; Lü N; Zheng S; Zhao QZ; Tang PZ Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Mar; 47(3):234-40. PubMed ID: 22805026 [TBL] [Abstract][Full Text] [Related]
20. Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity. Tao J; Li Y; Liu YQ; Wang L; Yang J; Dong J; Wu Y; Shen GX; Tu YT J Invest Dermatol; 2008 Aug; 128(8):1991-6. PubMed ID: 18385764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]